News

STARTING OFF ON THE RIGHT FOOT Our inhalation services include preliminary method development activities as the necessary first step for inhalation toxicology studies. The selection and characterization of the test atmosphere to be realistic and extensively measured...

IITRI now has access to multiple SARS-CoV-2 variants. Currently available: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma). Available soon: B.1.617.1 (Kappa) and B.1.617.2 (Delta) These variants are available for use in our assays (immunostain and neutralization) as well...

IITRI now offers an improved efficacy assay for looking at effects of drugs on SARS-CoV-2. Although this assay no longer includes a cytotoxicity readout, we offer a neutral red assay in BSl-2 instead if needed. This current assay uses immunostaining and provides more...

Ferret infection model: Since early in the pandemic, IITRI has been working on developing new animal models to test out therapeutics and treatments for COVID-19 (in addition to in vitro offerings of efficacy assays, neutralization assays, and surface decontaminant...

IITRI is proud to share the promising news of one of our partners, Moleculin!  Our team here at IITRI was contracted to perform additional in vitro testing of their drug candidate (WP1122) for antiviral effects against SARS-CoV-2. We used growth medium that more...

IITRI is now in custody of the a SARS-CoV-2 strain responsible for COVID-19. Our team is working on characterizing the strain for in vitro studies and in vivo modeling to test current vaccines and antivirals in addition to developing new treatments for this...